The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Multifaceted Role of Matrix Metalloproteinases in Neurodegenerative Diseases: Pathophysiological and Therapeutic Perspectives
Open accessAbstract
Neurodegeneration is the pathological condition, in which the nervous system or neuron loses its structure, function, or both, leading to progressive degeneration or the death of neurons, and well-defined associations of tissue system, resulting in clinical manifestations. Neuroinflammation has been shown to precede neurodegeneration in several neurodegenerative diseases (NDs). No drug is yet known to delay or treat neurodegeneration. Although the etiology and potential causes of NDs remain widely indefinable, matrix metalloproteinases (MMPs) evidently have a crucial role in the progression of NDs. MMPs, a protein family of zinc (Zn2+)-containing endopeptidases, are pivotal agents that are involved in various biological and pathological processes in the central nervous system (CNS). The current review delineates the several emerging evidence demonstrating the effects of MMPs in the progression of NDs, wherein they regulate several processes, such as (neuro)inflammation, microglial activation, amyloid peptide degradation, blood brain barrier (BBB) disruption, dopaminergic apoptosis, and α-synuclein modulation, leading to neurotoxicity and neuron death. Published papers to date were searched via PubMed, MEDLINE, etc., while using selective keywords highlighted in our manuscript. We also aim to shed a light on pathophysiological effect of MMPs in the CNS and focus our attention on its detrimental and beneficial effects in NDs, with a special focus on Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), multiple sclerosis (MS), and Huntington’s disease (HD), and discussed various therapeutic strategies targeting MMPs, which could serve as potential modulators in NDs. Over time, several agents have been developed in order to overcome challenges and open up the possibilities for making selective modulators of MMPs to decipher the multifaceted functions of MMPs in NDs. There is still a greater need to explore them in clinics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
The neuropathological diagnosis of Alzheimer's disease
DeTure, M. A., & Dickson, D. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0333-5 · Cited by 3,329
Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975
Amyloid Beta: Structure, Biology and Structure-Based Therapeutic Development
Chen, G.-F., Xu, T.-H., Yan, Y., Zhou, Y.-R., Jiang, Y., Melcher, K., & Xu, H. E. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.28 · Cited by 1,965
Biochemical and Biological Attributes of Matrix Metalloproteinases
Cui, N., Hu, M., & Khalil, R. A. (2017) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2017.02.005 · Cited by 1,359 · cited 1×
“The basic structure of MPs consists of a catalytic domain and pro peptide sequence [25,26].”
BackgroundApolipoprotein E controls cerebrovascular integrity via cyclophilin A
Bell, R. D., Winkler, E. A., Singh, I., Sagare, A. P., Deane, R., Wu, Z., Holtzman, D. M., Betsholtz, C., Armulik, A., Sallstrom, J., et al. (2012) · Nature · doi:10.1038/nature11087 · Cited by 1,293
Zhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., Wilson, B., Zhang, W., Zhou, Y., Hong, J.-S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2751com · Cited by 1,265 · cited 1×
“Indeed, damaged DAergic neurons can further activate microglia via the release of neuromelanin and α-synuclein, leading to ROS production [96].”
BackgroundIn vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200 · cited 7×
“An elevation in astrocytes and striatal neurons labeled by MMP-9 was also seen in the primate PD model (MPTP-injected macaques).”
BackgroundInfluentialWu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183
Jabłońska-Trypuć, A., Matejczyk, M., & Rosochacki, S. (2016) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2016.1161620 · Cited by 1,042
Mogi, M., Harada, M., Riederer, P., Narabayashi, H., Fujita, K., & Nagatsu, T. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90746-3 · Cited by 986
Newby, A. C. (2005) · Physiological Reviews · doi:10.1152/physrev.00048.2003 · Cited by 817
Turner, M. R., Cagnin, A., Turkheimer, F. E., Miller, C. C. J., Shaw, C. E., Brooks, D. J., Leigh, P. N., & Banati, R. B. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.012 · Cited by 737
Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis
Friese, M. A., Schattling, B., & Fugger, L. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.37 · Cited by 628
Matrix metalloproteinases and their multiple roles in neurodegenerative diseases
Rosenberg, G. A. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70016-x · Cited by 594
Metalloproteinases: Mediators of Pathology and Regeneration in the CNS
Yong, V. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1807 · Cited by 582 · cited 1×
“In addition, studies have also indicated MMPs in the vascular cognitive impairment (VCI)-associated neurodegeneration [5,18].”
BackgroundSolleiro-Villavicencio, H., & Rivas-Arancibia, S. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00114 · Cited by 463
Braak, H., Sastre, M., & Del Tredici, K. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0244-3 · Cited by 462
Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease
Gelders, G., Baekelandt, V., & Van der Perren, A. (2018) · Journal of Immunology Research · doi:10.1155/2018/4784268 · Cited by 430
How do immune cells overcome the blood-brain barrier in multiple sclerosis?
Larochelle, C., Alvarez, J. I., & Prat, A. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.04.066 · Cited by 405
McGeer, P. L., Schwab, C., Parent, A., & Doudet, D. (2003) · Annals of Neurology · doi:10.1002/ana.10728 · Cited by 400 · cited 2×
“The study is further encouraged by studies that were conducted on postmortem brain, which suggests the progressive DAergic damage of neurons in MPTP treated monkeys and humans for 10 years [88,98].”
BackgroundResultMatrix Metalloproteinase-9 Degrades Amyloid-β Fibrils in Vitro and Compact Plaques in Situ
Yan, P., Hu, X., Song, H., Yin, K., Bateman, R. J., Cirrito, J. R., Xiao, Q., Hsu, F. F., Turk, J. W., Xu, J., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602440200 · Cited by 380
Pott Godoy, M. C., Tarelli, R., Ferrari, C. C., Sarchi, M. I., & Pitossi, F. J. (2008) · Brain · doi:10.1093/brain/awn101 · Cited by 335 · cited 1×
“Some studies proposed that persistent microglial over-activation and proinflammatory cytokines production can contribute to the degeneration of neurons in PD [91,95].”
BackgroundDisruption of central nervous system barriers in multiple sclerosis
Alvarez, J. I., Cayrol, R., & Prat, A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.06.017 · Cited by 334
Backstrom, J. R., Lim, G. P., Cullen, M. J., & Tökés, Z. A. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-24-07910.1996 · Cited by 331
White, A. R., Du, T., Laughton, K. M., Volitakis, I., Sharples, R. A., Xilinas, M. E., Hoke, D. E., Holsinger, R. M. D., Evin, G., Cherny, R. A., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602487200 · Cited by 284
Winkler, E. A., Sengillo, J. D., Sagare, A. P., Zhao, Z., Ma, Q., Zuniga, E., Wang, Y., Zhong, Z., Sullivan, J. S., Griffin, J. H., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1401595111 · Cited by 238
Extracellular matrix degradation by metalloproteinases and central nervous system diseases
Lukes, A., Mun-Bryce, S., Lukes, M., & Rosenberg, G. A. (1999) · Molecular Neurobiology · doi:10.1007/bf02821717 · Cited by 230
IgG Reactivity in the Spinal Cord and Motor Cortex in Amyotrophic Lateral Sclerosis
Engelhardt, J. I., & Appel, S. H. (1990) · Archives of Neurology · doi:10.1001/archneur.1990.00530110068019 · Cited by 221
6-Hydroxydopamine-induced alterations in blood-brain barrier permeability
Carvey, P. M., Zhao, C. H., Hendey, B., Lum, H., Trachtenberg, J., Desai, B. S., Snyder, J., Zhu, Y. G., & Ling, Z. D. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04281.x · Cited by 218
MMPs in learning and memory and neuropsychiatric disorders
Beroun, A., Mitra, S., Michaluk, P., Pijet, B., Stefaniuk, M., & Kaczmarek, L. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03180-8 · Cited by 207
The energetic brain—A review from students to students
Bordone, M. P., Salman, M. M., Titus, H. E., Amini, E., Andersen, J. V., Chakraborti, B., Diuba, A. V., Dubouskaya, T. G., Ehrke, E., Espindola de Freitas, A., et al. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14829 · Cited by 205 · cited 1×
“Energy balance disturbances, to quality control of mitochondria or to glia-neuron metabolic interaction, may result in malfunctioning of brain circuit or even severe neurodegenerative disorders [77].”
BackgroundSelf-citationDisruption of neurovascular unit prior to motor neuron degeneration in amyotrophic lateral sclerosis
Miyazaki, K., Ohta, Y., Nagai, M., Morimoto, N., Kurata, T., Takehisa, Y., Ikeda, Y., Matsuura, T., & Abe, K. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22594 · Cited by 197
DESCHAMPS, A., & SPINALE, F. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.10.004 · Cited by 189 · cited 1×
“A variety of stimuli activates MMPs, including several growth factors and proinflammatory cytokines, which can commence an intracellular signaling process, resulting in the activation of nuclear factor kappa light chain enhancer of activated B cells (NFkB), Activator protein -1 (AP-1), or E26 transformation-specific (…”
BackgroundTNF-α knockout and minocycline treatment attenuates blood–brain barrier leakage in MPTP-treated mice
Zhao, C., Ling, Z., Newman, M. B., Bhatia, A., & Carvey, P. M. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.11.012 · Cited by 183 · cited 1×
“Leakage in BBB was demonstrated in animal PD models in areas of brain and was linked with DAergic neurodegeneration and microglial activation [106,107].”
BackgroundBjerke, M., Zetterberg, H., Edman, Å., Blennow, K., Wallin, A., & Andreasson, U. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110566 · Cited by 180
DECREASED mRNA EXPRESSION OF TIGHT JUNCTION PROTEINS IN LUMBAR SPINAL CORDS OF PATIENTS WITH ALS
Henkel, J. S., Beers, D. R., Wen, S., Bowser, R., & Appel, S. H. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a41228 · Cited by 153
Feng, W., Zhang, Y., Wang, Z., Xu, H., Wu, T., Marshall, C., Gao, J., & Xiao, M. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00688-1 · Cited by 150
Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer’s disease brain
Yoshiyama, Y., Asahina, M., & Hattori, T. (2000) · Acta Neuropathologica · doi:10.1007/pl00007428 · Cited by 128
Role of Matrix Metalloproteinase 3-mediated α-Synuclein Cleavage in Dopaminergic Cell Death
Choi, D.-H., Kim, Y.-J., Kim, Y.-G., Joh, T. H., Beal, M. F., & Kim, Y.-S. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.222430 · Cited by 123
Alzheimer’s Disease, Inflammation, and the Role of Antioxidants
Sinyor, B., Mineo, J., & Ochner, C. (2020) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-200171 · Cited by 120
Halliday, M. R., Pomara, N., Sagare, A. P., Mack, W. J., Frangione, B., & Zlokovic, B. V. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.3841 · Cited by 119
Morgan, L., Shah, B., Rivers, L. E., Barden, L., Groom, A. J., Chung, R., Higazi, D., Desmond, H., Smith, T., & Staddon, J. M. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.04.051 · Cited by 118
Insights into Alzheimer disease pathogenesis from studies in transgenic animal models
Schaeffer, E. L., Figueiró, M., & Gattaz, W. F. (2011) · Clinics · doi:10.1590/s1807-59322011001300006 · Cited by 114
Brain matrix metalloproteinase 1 levels are elevated in Alzheimer's disease
Leake, A., Morris, C. M., & Whateley, J. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01418-x · Cited by 95
Matrix Metalloproteinases as New Targets in Alzheimer’s Disease: Opportunities and Challenges
Zipfel, P., Rochais, C., Baranger, K., Rivera, S., & Dallemagne, P. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00352 · Cited by 94 · cited 2×
“have been obtained in the past two decades [1,2].”
BackgroundGarcía-González, L., Pilat, D., Baranger, K., & Rivera, S. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00244 · Cited by 88 · cited 1×
“Nevertheless, being considered to be multifaceted enzymes, MMPs mediate various biological and pathological pathways in CNS, where the outcome needs to be carefully assessed while allowing their inhibition, so as to anticipate/avoid undesirable side effects [65].”
BackgroundPERESS, N., PERILLO, E. D., & ZUCKER, S. (1995) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199501000-00002 · Cited by 81
Cited by
Energy metabolism in health and diseases
Liu, H., Wang, S., Wang, J., Guo, X., Song, Y., Fu, K., Gao, Z., Liu, D., He, W., & Yang, L.-L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02141-x · Cited by 399
Walker, K. A., Chen, J., Shi, L., Yang, Y., Fornage, M., Zhou, L., Schlosser, P., Surapaneni, A., Grams, M. E., Duggan, M. R., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf5681 · Cited by 148
Pharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions
Miculas, D. C., Negru, P. A., Bungau, S. G., Behl, T., Hassan, S. S. U., & Tit, D. M. (2022) · Cells · doi:10.3390/cells12010131 · Cited by 96
“Inflammation has now been observed in numerous investigations using postmortem tissues from samples of AD patients, but the role of inflammation in AD is not yet fully understood [91,92].”
BackgroundSelf-citationDhiman, S., Mannan, A., Taneja, A., Mohan, M., & Singh, T. G. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122537 · Cited by 25
Cai, M., Chen, S., Du, Y., Li, S., Dong, P., Wang, L., Yang, R., Hu, J., & Zhu, L. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-022-02052-4 · Cited by 4
Metadata
- Authors
- Behl, T., Kaur, G., Sehgal, A., Bhardwaj, S., Singh, S., Buhas, C., Judea-Pusta, C., Uivarosan, D., Munteanu, M. A., & Bungau, S.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-01-30
- Volume
- 22
- Issue
- 3
- Pages
- 1413
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3128820871
- Cited by
- 186
- References
- 48
- FWCI
- 10.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.